Educational research platform — not medical or investment advice. Verify all data before decisions.

ZEAL · OMX

Zealand Pharma

Peptide-focused biotech with amylin analog (petrelintide) and multiple partnered programs.

HQ Søborg, Denmark
Market cap Small
Focus Peptide therapeutics (amylin, glucagon, GLP-2)
Investor relations ↗
Last updated:Jul 15, 2026Source:SEC EDGAR + company IRVerified:Reviewed against latest filingsData provider:PeptidePlanet Research

Overview

Pipeline programs

5

Active trials

1

Upcoming catalysts

1

Indications

3
ObesityCongenital HyperinsulinismShort Bowel

AI research summary

Generated on demand from verified profile data.

The AI summarizer only sees the verified fields on this page. Every numbered citation maps to a source in the legend below.

Pipeline

1

Clinical trials

1

Upcoming catalysts

1
  • Oct 18, 2026

    Survodutide Phase 3 update window

    Readout · Window

    Source ↗

Timeline

Merged approvals, trial milestones, and catalysts. Newest first.

4

  1. Jun 01, 2027 · Trial Milestone

    Phase 3 · SYNCHRONIZE-1 — survodutide in obesity — primary completion (recruiting)

    ClinicalTrials.gov ↗

  2. Oct 18, 2026 · Corporate

    Survodutide Phase 3 update window

    Source ↗

  3. Jun 24, 2024 · Partnership

    Zealand announces global collaboration on petrelintide with a large-pharma partner.

    Zealand Pharma IR ↗

  4. Aug 31, 2023 · Trial Milestone

    Zealand reports Phase 1b topline for amylin analog petrelintide (ZP8396) in obesity.

    Zealand Pharma IR ↗

Verified sources

  1. [1]
    Zealand Pharma IR — Zealand Pharmaretrieved 2026-07-15
  2. [2]
    ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15

SEC filings search: EDGAR ↗

More companies

LLY

Eli Lilly

Incretin therapies (GLP-1 / GIP / glucagon triagonists)

NVO

Novo Nordisk

GLP-1 analogs, amylin, and combination peptides

AMGN

Amgen

Bispecific peptide antibody conjugates

VKTX

Viking Therapeutics

Dual GLP-1/GIP receptor agonists